Latest Consumer Healthcare News

The Hydration Pharmaceuticals Company (ASX:HPC) has sharply reduced its operating losses, with Hydralyte LLC recording its first monthly EBITDA profit in August. The group remains loss-making overall, but improved margins and a lower cost base are beginning to show in the numbers.

Wellnex Life has agreed to sell its Pain Away brand to Mentholatum Australasia for up to A$21.3 million, aiming to wipe out debt and sharpen its strategic focus.

Wellnex Life reports a $2.4 million EBITDA improvement in H1 FY26 and reaches breakeven by Q2, supported by strong Pain Away sales and expanded distribution.

Wellnex Life has secured a significant opening order from global partner Haleon for its Liquid Paracetamol and Ibuprofen softgel products in the UAE, marking the fourth national market in Haleon's distribution network. This milestone supports Wellnex's revenue forecasts for 2025 and underscores its strategic focus on innovative healthcare products.

Wellnex Life Limited has expanded its financing with a new A$2.5 million loan facility, enhancing its financial flexibility to support ongoing business growth and settle long-term obligations.

Wellnex Life reported a strong 40.4% revenue increase to $23.6 million in FY25, alongside a 57% improvement in normalised EBITDA loss, signaling progress despite ongoing investment costs.

Wellnex Life announces the resignation of joint CEO George Karafotias, with Zack Bozinovski stepping up as sole CEO. The company plans to repay a $705,000 director loan within 90 days.

Wellnex Life Limited reported a robust Q4 FY25 with a 22% sales increase and positive operational cash flow, underpinning its strategic growth initiatives backed by new debt funding.

Wellnex Life Limited reports a robust 46% revenue increase and successful AIM listing, setting the stage for UK and European expansion.

Wellnex Life Limited announces key board and management changes following its successful AIM Market dual listing, including the resignation of its Non-Executive Chairman and appointment of a joint CEO to drive growth.

Wellnex Life Limited has locked in A$9 million in conditional commitments to support its proposed dual listing on the London Stock Exchange’s AIM market, alongside launching a 1:1 entitlement offer for existing shareholders.

Wellnex Life Limited has initiated a $22.1 million entitlement offer priced at $0.65 per share, coinciding with its proposed dual listing on the London Stock Exchange's AIM market, driven by strong UK institutional interest.